diarrhea%20in%20adults%20-%20chronic
DIARRHEA IN ADULTS - CHRONIC
Chronic diarrhea is defined as the abnormal passage of ≥3 loose or liquid stools per day for ≥4 week with or without a daily stool weight >200 g/day.
The definition of chronic diarrhea based on symptoms alone will lead to an overlap with functional bowel disorders eg irritable bowel syndrome.
Diarrhea that is continuous or nocturnal and lasting <3 months is more likely due to an organic disease.
The absence of abdominal pain during defecation and presence of weight loss are points against the diagnosis of functional bowel syndrome eg irritable bowel syndrome.

Diarrhea in Adults - Chronic Drug Information

Drug Information
Bioflor
Saccharomyces boulardii

Indication: Acute infectious diarrhoea in infants, childn & adults. Prevention of antibiotic-associated diarrhoea in c...

Agiolax
plantago ovata husks + plantago seeds + sennosides

Indication: Traditionally used for constipation.

Indication: Symptomatic control of acute & chronic diarrhea; reduce number & vol of stools & harden their cons...

Indication: Treatment & prophylaxis of intestinal dysmicrobism & subsequent endogenous dysvitaminosis. Therapy for...

Indication: Relief of constipation eg, constipation in pregnancy & maintenance of regularity. Bowel function managemen...

Indication: Control & symptomatic relief of acute nonspecific diarrhoea & chronic diarrhoea associated w/ inflamma...

Indication: Acute & chronic diarrhoea. Pain associated w/ oesogastroduodenal & colic disease.

Indication: Adjunctive therapy in management of acute & chronic diarrhea.

Indication: Acute diarrhoea, prevention of absorption in oral intoxications & acceleration of elimination in intoxicat...

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.